Investor David Bogart holds 8.1% of Conexeu

Conexeu Sciences Inc. investor David Bogart reports beneficial ownership of 2,293,750 shares of Common Stock of CNXU, representing 8.1% of the class.

Rhea-AI Filing Summary

Conexeu Sciences Inc. investor David Bogart reports beneficial ownership of 2,293,750 shares of Common Stock of CNXU, representing 8.1% of the class. These shares include 1,062,500 held directly, 431,250 held through 0865546 B.C. Ltd., 50,000 from vested, exercisable stock options, and 750,000 from vested, exercisable performance warrants.

The ownership percentage is calculated using 27,397,164 shares of Common Stock outstanding as of August 17, 2026, plus the reporting person’s vested options and warrants deemed outstanding under Rule 13d-3(d)(1)(i). An additional 250,000 shares underlying unvested performance warrants are excluded from this ownership calculation.

Key Figures

Beneficial ownership: 2,293,750 shares Ownership percentage: 8.1 % Shares outstanding: 27,397,164 shares +5 more

8 metrics

Beneficial ownership 2,293,750 shares Total Conexeu Sciences Inc. Common Stock beneficially owned by David Bogart

Ownership percentage 8.1 % Percent of Conexeu Sciences Inc. Common Stock class beneficially owned by David Bogart

Shares outstanding 27,397,164 shares Conexeu Sciences Inc. Common Stock outstanding as of August 17, 2026

Directly held shares 1,062,500 shares Common Stock held directly by David Bogart

Shares via 0865546 B.C. Ltd. 431,250 shares Common Stock held by 0865546 B.C. Ltd. with Bogart’s sole voting and dispositive power

Vested options 50,000 shares Shares issuable upon exercise of vested, exercisable stock options

Vested performance warrants 750,000 shares Shares issuable upon exercise of vested, exercisable performance warrants

Unvested performance warrants 250,000 shares Shares underlying unvested performance warrants contingent on a 510(k) application

Key Terms

beneficially owned, sole dispositive power, Rule 13d-3(d)(1)(i), performance warrants, +2 more

6 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 2,293,750"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power financial

"Sole Dispositive Power 2,293,750.00 8 | Shared Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Rule 13d-3(d)(1)(i) regulatory

"deemed to be outstanding for the purpose of computing the Reporting Person's percentage ownership pursuant to Rule 13d-3(d)(1)(i)"

performance warrants financial

"750,000 shares of Common Stock issuable upon exercise of performance warrants (the "Performance Warrants")"

510(k) application medical

"will not vest until the submission of a 510(k) application to the U.S. Food and Drug Administration"

A 510(k) application is a regulatory submission to the U.S. Food and Drug Administration showing that a new medical device is substantially similar to an already approved device, so it can be cleared for marketing without the longest, most rigorous approval process. For investors, a cleared 510(k) means faster, lower-cost market access and lower regulatory risk compared with full approvals, which can speed revenue and reduce uncertainty — like getting permission to sell a new model because it’s close to an existing one.

sole voting power financial

"5 | Sole Voting Power 2,293,750.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Conexeu Sciences Inc. (CNXU) shares does David Bogart beneficially own?

David Bogart beneficially owns 2,293,750 shares of Conexeu Sciences Inc. Common Stock. This total includes directly held shares, shares held through 0865546 B.C. Ltd., and shares issuable from vested stock options and performance warrants.

What percentage of Conexeu Sciences Inc. (CNXU) does David Bogart own according to this Schedule 13G?

David Bogart reports owning 8.1% of Conexeu Sciences Inc.’s Common Stock. The percentage is based on outstanding shares plus his vested, exercisable options and performance warrants deemed outstanding under Rule 13d-3(d)(1)(i).

How many Conexeu Sciences Inc. (CNXU) shares are outstanding for the 13G ownership calculation?

The ownership calculation uses 27,397,164 shares of Conexeu Sciences Inc. Common Stock outstanding as of August 17, 2026, plus Bogart’s vested options and warrants deemed outstanding for calculating his percentage ownership.

What portion of David Bogart’s Conexeu Sciences Inc. (CNXU) holding comes from options and warrants?

David Bogart’s holdings include 50,000 shares from vested, exercisable stock options and 750,000 shares from vested, exercisable performance warrants. These instruments are counted as beneficially owned because they are currently exercisable.

Are all of David Bogart’s Conexeu Sciences Inc. (CNXU) performance warrants included in the 8.1% ownership?

No. The 8.1% includes 750,000 shares from vested performance warrants but excludes 250,000 shares underlying unvested performance warrants. Those unvested warrants depend on submission of a 510(k) application to the U.S. FDA.

Does David Bogart have sole or shared voting power over his Conexeu Sciences Inc. (CNXU) shares?

David Bogart reports 2,293,750 shares with sole voting and dispositive power and 0 shares with shared voting or dispositive power. This includes shares held personally and through 0865546 B.C. Ltd. over which he has sole control.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2026 - 06:03 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Conexeu Sciences Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

20715F100

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 20715F100

1

Names of Reporting Persons

David Bogart

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,293,750.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,293,750.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,293,750.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.1 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Explanatory Notes: (1) The number in Rows 5, 7 and 9 consists of (i) 1,062,500 shares of Common Stock held directly by the Reporting Person, (ii) 431,250 shares of Common Stock held by 0865546 B.C. Ltd., a company over which the Reporting Person has sole voting and dispositive power, (iii) 50,000 shares of Common Stock issuable upon exercise of stock options that have vested and are currently exercisable (the "Vested Options"), and (iv) 750,000 shares of Common Stock issuable upon exercise of performance warrants (the "Performance Warrants") that have vested and are currently exercisable (the "Vested Warrants"), and excludes 250,000 shares of Common Stock issuable upon exercise of Performance Warrants that have not yet vested and will not vest until the submission of a 510(k) application to the U.S. Food and Drug Administration (the "Unvested Warrants"). (2) The percentage in Row 11 is calculated based on (i) 27,397,164 shares of Common Stock outstanding as of August 17, 2026, (ii) 50,000 shares of Common Stock issuable upon exercise of the Vested Options held by the Reporting Person, and (iii) 750,000 shares of Common Stock issuable upon exercise of the Vested Warrants held by the Reporting Person, in each case deemed to be outstanding for the purpose of computing the Reporting Person's percentage ownership pursuant to Rule 13d-3(d)(1)(i) under the Act. The Unvested Warrants are excluded from this calculation.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Conexeu Sciences Inc.
(b)	Address of issuer's principal executive offices: Suite 880, 50 West Liberty Street, Reno, NEVADA 89501
Item 2.
(a)	Name of person filing: David Bogart (the "Reporting Person")
(b)	Address or principal business office or, if none, residence: c/o Conexeu Sciences Inc. Suite 880, 50 West Liberty Street Reno, NV 89501, USA
(c)	Citizenship: Canada
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 20715F100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,293,750
(b)	Percent of class: 8.10 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2,293,750
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2,293,750
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

David Bogart

Signature:	/s/ David Bogart
Name/Title:	David Bogart
Date:	08/17/2026